Study Design and Baseline Characteristics of APOLLO : A Phase 3 Study of Bitopertin in Erythropoietic Protoporphyria and X‐Linked Protoporphyria

ABSTRACT Erythropoietic protoporphyria (EPP) and X‐linked protoporphyria (XLP) are characterized by protoporphyrin IX (PPIX) accumulation, causing debilitating cutaneous phototoxic reactions and, in some cases, protoporphyric hepatopathy. Glycine transporter 1 (GlyT1) supplies extracellular glycine for erythroid heme biosynthesis. Bitopertin is an investigational oral GlyT1 inhibitor shown to significantly reduce PPIX and improve light tolerance and quality of life in patients with EPP or XLP. APOLLO is a global randomized, double‐blind, placebo‐controlled Phase 3 study designed to confirm the safety, tolerability, and efficacy of bitopertin in adults and adolescents with EPP or XLP. Eligible participants were ≥ 12 years of age with diagnosis by biochemical and/or genetic testing and randomized 1:1 to receive once‐daily oral bitopertin 60 mg or placebo over 24 weeks. Co‐primary endpoints are percent change in whole blood metal‐free PPIX and average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 and 18:00 after 24 weeks. The general design and participants' baseline characteristics are described herein. Between April 2025 and March 2026, 199 patients were screened at 28 study sites in the United States, Canada, Europe, United Kingdom, and Australia; 183 participants were randomized. Mean (SD) age was 37.1 ± 17.1 years; 59% were female and 91% were White. Most participants (93%) had EPP, whereas 7% had XLP. Overall, 60% had not received prior treatment for EPP; 28% and 18% previously received afamelanotide or dersimelagon, respectively. Adolescents (12 to < 18 years) represented 19% of enrolled participants, and most adolescents (85%) had not previously received afamelanotide or dersimelagon. APOLLO is designed to evaluate bitopertin as a potential disease‐modifying therapy for EPP and XLP. Baseline demographic and disease characteristics were consistent with prior EPP/XLP and generally support the relevance of the study's safety and efficacy findings to the broader EPP/XLP population.

Authors

Institutions

Publication Details

Journal
The Journal of Dermatology
Published
2026-11-15
DOI
https://doi.org/10.1111/1346-8138.70564
Primary Topic
Porphyrin Metabolism and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Study Design and Baseline Characteristics of APOLLO : A Phase 3 Study of Bitopertin in Erythropoietic Protoporphyria and X‐Linked Protoporphyria

Bruce Wang, Ilja Kubisch, Mark S. Amster, Petra De Haes et al.
The Journal of Dermatology
Porphyrin Metabolism and Disorders
article

Study Design and Baseline Characteristics of APOLLO : A Phase 3 Study of Bitopertin in Erythropoietic Protoporphyria and X‐Linked Protoporphyria

Bruce Wang, Ilja Kubisch, Mark S. Amster, Petra De Haes, Robert Sarkany, Manisha Balwani, Laurent Gouya, Will Savage, Gayle Ross, Amy K. Dickey, Manuchehr Darani, Edward Cordasco, Melanie P. Chin, Cynthia Levy, Herbert L. Bonkovsky, Tasneem F. Mohammad, Karl E. Anderson, Janneke G. Langendonk, Sioḃán Keel, Manuel P. Pereira, APOLLO Investigators
article en

Abstract

ABSTRACT Erythropoietic protoporphyria (EPP) and X‐linked protoporphyria (XLP) are characterized by protoporphyrin IX (PPIX) accumulation, causing debilitating cutaneous phototoxic reactions and, in some cases, protoporphyric hepatopathy. Glycine transporter 1 (GlyT1) supplies extracellular glycine for erythroid heme biosynthesis. Bitopertin is an investigational oral GlyT1 inhibitor shown to significantly reduce PPIX and improve light tolerance and quality of life in patients with EPP or XLP. APOLLO is a global randomized, double‐blind, placebo‐controlled Phase 3 study designed to confirm the safety, tolerability, and efficacy of bitopertin in adults and adolescents with EPP or XLP. Eligible participants were ≥ 12 years of age with diagnosis by biochemical and/or genetic testing and randomized 1:1 to receive once‐daily oral bitopertin 60 mg or placebo over 24 weeks. Co‐primary endpoints are percent change in whole blood metal‐free PPIX and average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 and 18:00 after 24 weeks. The general design and participants' baseline characteristics are described herein. Between April 2025 and March 2026, 199 patients were screened at 28 study sites in the United States, Canada, Europe, United Kingdom, and Australia; 183 participants were randomized. Mean (SD) age was 37.1 ± 17.1 years; 59% were female and 91% were White. Most participants (93%) had EPP, whereas 7% had XLP. Overall, 60% had not received prior treatment for EPP; 28% and 18% previously received afamelanotide or dersimelagon, respectively. Adolescents (12 to < 18 years) represented 19% of enrolled participants, and most adolescents (85%) had not previously received afamelanotide or dersimelagon. APOLLO is designed to evaluate bitopertin as a potential disease‐modifying therapy for EPP and XLP. Baseline demographic and disease characteristics were consistent with prior EPP/XLP and generally support the relevance of the study's safety and efficacy findings to the broader EPP/XLP population.

The Journal of Dermatology
Atrium Health Wake Forest Baptist (US), The Royal Melbourne Hospital (AU), Harvard University (US), University of Miami (US), Henry Ford Health System (US), University of California, San Francisco (US), University of Washington (US), Université Paris Cité (FR), Universitair Ziekenhuis Leuven (BE), Erasmus MC (NL), Humboldt-Universität zu Berlin (DE), Massachusetts General Hospital (US), Fred Hutch Cancer Center (US), Klinikum Chemnitz (DE), Remington-Davis Clinical Research (US), Disc Medicine, Inc. (United States) (US), Wake Forest University Health Sciences (US), Wake Forest University (US), The University of Texas Medical Branch at Galveston (US), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE), Icahn School of Medicine at Mount Sinai (US)
Porphyrin Metabolism and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon